CRSP - CRISPR Therapeutics AG

QQQ $ 439.97 $ 4.77 (1.1 %)

DIA $ 388.40 $ 1.68 (0.43 %)

SPY $ 516.34 $ 5.28 (1.03 %)

TLT $ 90.16 $ 0.35 (0.39 %)

GLD $ 215.21 $ 2.24 (1.05 %)

Previous Close

$ 57.06

Open

$ 56.39

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 55.84 - $ 57.40

52 Week Range

$ 37.55 - $ 91.10

Volume

1,448,979

Average Volume

Market Cap

4.52B

Beta (5Y Monthly)

$ 1.08

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	02-21-2024	12-31-2023	10-K
2	11-06-2023	09-30-2023	10-Q
3	08-07-2023	06-30-2023	10-Q
4	05-08-2023	03-31-2023	10-Q
5	02-21-2023	12-31-2022	10-K
6	11-01-2022	09-30-2022	10-Q
7	08-08-2022	06-30-2022	10-Q
8	05-09-2022	03-31-2022	10-Q
9	02-15-2022	12-31-2021	10-K
10	11-03-2021	09-30-2021	10-Q
11	07-29-2021	06-30-2021	10-Q
12	04-27-2021	03-31-2021	10-Q
13	02-16-2021	12-31-2020	10-K
14	10-28-2020	09-30-2020	10-Q
15	07-27-2020	06-30-2020	10-Q
16	04-28-2020	03-31-2020	10-Q
17	02-12-2020	12-31-2019	10-K
18	10-28-2019	09-30-2019	10-Q
19	07-29-2019	06-30-2019	10-Q
20	04-29-2019	03-31-2019	10-Q
21	02-25-2019	12-31-2018	10-K
22	11-07-2018	09-30-2018	10-Q
23	08-07-2018	06-30-2018	10-Q
24	05-08-2018	03-31-2018	10-Q
25	03-08-2018	12-31-2017	10-K
26	11-08-2017	09-30-2017	10-Q
27	08-10-2017	06-30-2017	10-Q
28	05-11-2017	03-31-2017	10-Q
29	03-10-2017	12-31-2016	10-K
30	11-22-2016	09-30-2016	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Citigroup Maintains Buy on CRISPR Therapeu...
04/18/2024 16:12:47

Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target from ...

Needham Reiterates Buy on CRISPR Therapeut...
04/11/2024 10:38:49

Needham analyst Gil Blum reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and maintains $90 price target.

if-you-invested-1000-in-this-stock-5-years-ago-you-would-have-2000-today

If You Invested $1000 In This Stock 5 Year...
03/19/2024 15:31:42

cathie-woods-ark-invest-keeps-dumping-coinbase-shares-amid-bitcoin-crypto-buzz

Cathie Wood's Ark Invest Keeps Dumping Coi...
03/13/2024 03:57:30

On Tuesday, Cathie Wood-led Ark Invest made a significant move by offloading a substantial number of shares in Coinbase Global ...

Mizuho Maintains Buy on CRISPR Therapeutic...
03/06/2024 13:09:44

Mizuho analyst Salim Syed maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target from $82 to $99.

median-drug-prices-for-rare-diseases-hit-300k-in-2023-report-highlights-lack-of-clear-rationale-behind-escalating-drug-prices

Median Drug Prices For Rare Diseases Hit $...
02/26/2024 17:14:35

Latest pharmaceutical trends in the U.S. as drug prices surged 35% in 2023. Uncover insights into the industry's focus on r...

Morgan Stanley Maintains Underweight on CR...
02/26/2024 15:47:08

Morgan Stanley analyst Terence Flynn maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Underweight and raises the price tar...

if-you-invested-1000-in-this-stock-5-years-ago-you-would-have-2100-today

If You Invested $1000 In This Stock 5 Year...
02/23/2024 19:00:22

Smart Money Is Betting Big In CRSP Options
02/22/2024 18:15:54

RBC Capital Maintains Sector Perform on CR...
02/22/2024 17:40:02

RBC Capital analyst Luca Issi maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Sector Perform and raises the price target ...

Analog Devices To Rally Around 19%? Here A...
02/22/2024 12:23:19

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

Chardan Capital Maintains Buy on CRISPR Th...
02/22/2024 10:44:20

Chardan Capital analyst Geulah Livshits maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target f...

Needham Maintains Buy on CRISPR Therapeuti...
02/21/2024 16:40:58

Needham analyst Gil Blum maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target from $88 to $90.

CRISPR Therapeutics Q4 EPS $1.10 Vs $(1.41...
02/21/2024 12:35:38

whats-going-on-with-crispr-therapeutics-stock

What's Going On With Crispr Therapeutics S...
02/15/2024 16:36:47

Crispr Therapeutics shares are trading higher Thursday after Wolfe Research analyst Andy Chen initiated coverage on Crispr Ther...

reliance-steel--aluminum-posts-upbeat-earnings-joins-jfrog-applovin-shake-shack-and-other-big-stocks-moving-higher-on-thursday

Reliance Steel & Aluminum Posts Upbeat Ear...
02/15/2024 15:23:41

U.S. stocks were mostly higher, with the Dow Jones index gaining more than 150 points on Wednesday.

Wolfe Research Initiates Coverage On CRISP...
02/15/2024 11:58:43

Wolfe Research analyst Andy Chen initiates coverage on CRISPR Therapeutics (NASDAQ:CRSP) with a Peer Perform rating.

Check Out What Whales Are Doing With CRSP
02/14/2024 18:31:23

CRISPR Therapeutics Announces $280M Regist...
02/13/2024 13:43:43

- Led by new investor EcoR1 Capital and SR One with participation from existing and new investors - - Well positioned to execut...

European Commission Approves First CRISPR/...
02/13/2024 07:32:02

CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for seri...